Radionuclide Therapy (2022. xxiii, 387 S. XXIII, 387 p. 122 illus., 101 illus. in color. 254)

個数:

Radionuclide Therapy (2022. xxiii, 387 S. XXIII, 387 p. 122 illus., 101 illus. in color. 254)

  • 在庫がございません。海外の書籍取次会社を通じて出版社等からお取り寄せいたします。
    通常6~9週間ほどで発送の見込みですが、商品によってはさらに時間がかかることもございます。
    重要ご説明事項
    1. 納期遅延や、ご入手不能となる場合がございます。
    2. 複数冊ご注文の場合は、ご注文数量が揃ってからまとめて発送いたします。
    3. 美品のご指定は承りかねます。

    ●3Dセキュア導入とクレジットカードによるお支払いについて

  • 提携先の海外書籍取次会社に在庫がございます。通常3週間で発送いたします。
    重要ご説明事項
    1. 納期遅延や、ご入手不能となる場合が若干ございます。
    2. 複数冊ご注文の場合は、ご注文数量が揃ってからまとめて発送いたします。
    3. 美品のご指定は承りかねます。

    ●3Dセキュア導入とクレジットカードによるお支払いについて
  • 【入荷遅延について】
    世界情勢の影響により、海外からお取り寄せとなる洋書・洋古書の入荷が、表示している標準的な納期よりも遅延する場合がございます。
    おそれいりますが、あらかじめご了承くださいますようお願い申し上げます。
  • ◆画像の表紙や帯等は実物とは異なる場合があります。
  • ◆ウェブストアでの洋書販売価格は、弊社店舗等での販売価格とは異なります。
    また、洋書販売価格は、ご注文確定時点での日本円価格となります。
    ご注文確定後に、同じ洋書の販売価格が変動しても、それは反映されません。
  • 製本 Hardcover:ハードカバー版
  • 商品コード 9783030972196

Full Description

The main purpose of this book is to create a reference for the indications, contraindications, patient selection, treatment practice, treatment side effect management, and follow-up of radionuclide treatments.
Besides standard methods such as surgery, chemotherapy, radiotherapy, and hormone therapy, newly developed biological treatments, targeted treatments, personalized treatments, external beam radiotherapy, and targeted radionuclide treatments have begun to take their place in professional practice. 

Nuclear medicine, in addition to its role as a tracer of cancer, also assumes the role of treating with radioactive molecules directed to the cancer it traces. These traceable next-generation radionuclide treatments, whose efficacy and reliability have been proven and where diagnosis, treatment, and follow-up are carried out together, are increasingly included in oncology practice together with the new developed radiopharmaceuticals, ensuring a high rate of damage to cancer cells while protecting the surrounding normal tissues. Molecular cancer treatment will become more effective with individualized next-generation traceable radionuclide treatments, which will be shaped by genetic studies in the future.

Radionuclide treatments for many cancer types and benign diseases are presented by experienced nuclear medicine experts in the light of their own experience and case studies, while systemic treatments in common cancer types and side effect management of these treatments are summarized by medical oncologists.  

This book will be of interest to nuclear medicine physicians as well as oncologists.

Contents

Part-1: Basic Information. Basic properties and preparation of radiopharmaceuticals used in radionuclide therapy.- Physical Bases of Radionuclide Therapy (Biological Effects and Properties of Particle Radiation).- Fundamentals of radiation safety and dosimetric approach in radionuclide therapy applications. Part-2: Clinical Information: Thyroid Diseases. Radionuclide Therapy in Benign Thyroid Diseases: Nodular Goiter Disease.- Radionuclide Therapy in Benign Thyroid Diseases: Graves' Disease.- Radionuclide Therapy in Malignant Thyroid Diseases: Differentiated Thyroid Cancer.- Radionuclide Therapy in Malignant Thyroid Diseases: Medullary Thyroid Cancer.- Systemic Treatments and related side effects in Thyroid Cancer. Part-2: Clinical Information: Neuroendocrine Tumors. Radionuclide Therapy in Neuroendocrine Tumors. Systemic Treatments and related side effects in Neuroendocrine Tumors. Part-4: Clinical Information: Neuroectodermal Tumors. Radionuclide Therapy in Neuroectodermal Tumors.- Systemic Treatments and  related side effects in Neuroectodermal Tumors. Part-5: Clinical Information: Liver Tumors. Radionuclide Therapy in Liver Tumors. Systemic Treatments and  related side effects in Liver Tumors. Part-6: Clinical Information:  Prostate Cancer. Radionuclide Therapy in Prostate Cancer.- Systemic Treatments and related side effects in Prostate Cancer. Part-7: Clinical Information:  Bone and Joint Diseases. Radionuclide Therapy in Joint Diseases: Radiosynovectomy.- Radionuclide Pain Palliation Therapy.- Radionuclide Therapy with Alpha Emitting Agents in Bone Metastases. Part-8: Clinical Information: Lymphoproliferative Diseases. Radionuclide Therapy in Lymphoproliferative Diseases. Part-9: Radioimmunotherapy. Basics and clinical applications of radioimmunotherapy. Part-10: Intracavitary Radionuclide Therapy. Intracavitaryradionuclide applications.

最近チェックした商品